VKTX News and Press, Viking Therapeutics Inc.

2024-06-27 06:00:08 ET Michael Ulz from Morgan Stanley issued a price target of $105.00 for VKTX on 2024-06-27 04:57:00. The adjusted price target was set to $105.00. At the time of the announcement, VKTX was trading at $47.39. The overall price target consensus is at $9...

2024-06-26 07:45:00 ET Innovation stocks can be incredible wealth escalators. Technological breakthroughs can open up new high-value markets or unlock unique ways to target underserved sectors. Archer Aviation (NYSE: ACHR) and Viking Therapeutics (NASDAQ: VKTX) are prime...

2024-06-26 06:25:00 ET Summary U.S. domestic markets experienced significant gains during the recent period between Index selection dates (May 9, 2024 – June 12, 2024). The BUZZ Index returned 5.37% during the month of May compared to a return of 4.96% for the S&P 500 I...

2024-06-25 11:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-25 08:15:04 ET H.C. Wainwright analyst issues BUY recommendation for VKTX on June 25, 2024 06:44AM ET. The previous analyst recommendation was Buy. VKTX was trading at $52.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...

Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association PR Newswire Company's Receptor Co-Agonists Demonstrate Potent Body Weight Reductions, Decreased Food Intake and ...

2024-06-23 14:00:00 ET More on Eli Lilly, Novo Nordisk Eli Lilly: The Party Is Probably Nearing The End Novo Nordisk: Leading The Fight Against Diabetes And Obesity SA Asks: Who will launch the next big weight-loss drug? SA Asks: Is Eli Lilly or Novo No...

2024-06-18 07:50:00 ET Viking Therapeutics (NASDAQ: VKTX) is at an exciting point in its history. While it doesn't have any medicines approved for sale at the moment, it has a couple of mid-stage programs that are shaping up to make a big splash in their target markets, assuming the...

2024-06-17 09:13:40 ET Summary Viking Therapeutics shows promise with their VK2735 drug demonstrating significant weight loss in Phase 2 trials. Despite strong data, Viking faces intense competition and strategic challenges in a market dominated by Novo Nordisk and Eli Lilly. ...

2024-06-15 09:31:00 ET The S&P 500 remains near record levels as the markets have been strong this year. Finding good stocks to buy in such a hot market can be challenging. But a couple of growth stocks with lots of potential, based on their price targets from Wall Street, are V...